

# Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/M096770AFB17EN.html>

Date: April 2024

Pages: 214

Price: US\$ 6,499.00 (Single User License)

ID: M096770AFB17EN

## Abstracts

The 7 major multiple myeloma markets reached a value of US\$ 16.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 38.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8% during 2024-2034.

The multiple myeloma market has been comprehensively analyzed in IMARC's new report titled "Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Multiple myeloma is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies which protect against infection. Multiple myeloma involves an excessive growth of the cells crowding out normal cells in the bone marrow that produce red blood cells, platelets, and other white blood cells. Early on, patients having multiple myeloma might not notice any symptoms. But over time, they may develop common symptoms which include bone pain, weakness and fatigue, weight loss and loss of appetite, stomach problems, confusion, frequent infections, severe thirst, weakness or numbness in arms and legs, etc. Multiple myeloma can be hard to diagnose as it usually has few or no symptoms in the initial stages. Diagnosis for multiple myeloma may involve a range of blood tests, urine tests and bone or bone marrow tests. A number of these tests may also be used to assess the extent of the disease and to plan and monitor treatment.

One of the biggest drivers of the multiple myeloma market is the rising geriatric population. Since the incidence of multiple myeloma increases with age and rarely happens in people younger than 45 years of age, we expect a continuous growth in the global ageing population to create a positive impact on the multiple myeloma market. Furthermore, a rising prevalence of physical inactivity, overweight, obesity, and diabetes are also expected to drive this market as these factors are also associated with an

increasing incidence and mortality of this indication. Multiple myeloma is now treated like a chronic disorder catalyzed by the rising efficiency and safety of currently available treatments. The cost of therapy for multiple myeloma, however, has become increasingly high as patients are living longer and use these treatments for extended periods of time. This cost burden on both payers and providers, however, will get some relief once generic versions for some of the key drugs are launched across the major markets.

IMARC Group's new report provides an exhaustive analysis of the multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple myeloma market in any manner

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

#### Analysis Covered Across Each Country

*Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-20...*

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the multiple myeloma market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the multiple myeloma market  
Reimbursement scenario in the market  
In-market and pipeline drugs

#### Competitive Landscape:

This report also provides a detailed analysis of the current multiple myeloma marketed drugs and late-stage pipeline drugs.

#### In-Market Drugs

Drug overview  
Mechanism of action  
Regulatory status  
Clinical trial results  
Drug uptake and market performance

#### Late-Stage Pipeline Drugs

Drug overview  
Mechanism of action  
Regulatory status  
Clinical trial results  
Drug uptake and market performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

#### Key Questions Answered in this Report:

##### Market Insights

How has the multiple myeloma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the multiple myeloma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the multiple myeloma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the size of the multiple myeloma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of multiple myeloma?

What will be the growth rate of patients across the seven major markets?

## Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for multiple myeloma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple myeloma market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 MULTIPLE MYELOMA - INTRODUCTION**

- 4.1 Overview
- 4.2 Epidemiology (2018-2023) and Forecast (?2024-2034?)
- 4.3 Market Overview (2018-2023) and Forecast (?2024-2034?)
- 4.4 Competitive Intelligence

### **5 MULTIPLE MYELOMA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 MULTIPLE MYELOMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets

- 7.2.1 Epidemiology Scenario (2018-2023)
- 7.2.2 Epidemiology Forecast (?2024-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (?2024-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (?2024-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (?2024-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (?2024-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (?2024-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (?2024-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (?2024-2034?)

## **8 MULTIPLE MYELOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 MULTIPLE MYELOMA - UNMET NEEDS**

## **10 MULTIPLE MYELOMA - KEY ENDPOINTS OF TREATMENT**

## **11 MULTIPLE MYELOMA - MARKETED PRODUCTS**

- 11.1 List of Multiple Myeloma Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Revlimid (Lenalidomide) - Celgene
    - 11.1.1.1 Drug Overview

- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Sarclisa (Isatuximab) - Sanofi
  - 11.1.2.1 Drug Overview
  - 11.1.2.2 Mechanism of Action
  - 11.1.2.3 Regulatory Status
  - 11.1.2.4 Clinical Trial Results
  - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Xpovio (Selinexor) - Karyopharm
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Empliciti (Elotuzumab) - Bristol Myers Squibb/AbbVie
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.

## **12 MULTIPLE MYELOMA - PIPELINE DRUGS**

- 12.1 List of Multiple Myeloma Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 Binimetinib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy

- 12.1.1.5 Regulatory Status
- 12.1.2 Elranatamab - Pfizer
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 Iberdomide - Celgene, Bristol-Myers Squibb
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Masitinib - AB Science
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.

## **13. MULTIPLE MYELOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14 MULTIPLE MYELOMA - MARKET SCENARIO**

- 14.1 Market Scenario - Key Insights
- 14.2 Market Scenario - Top 7 Markets
  - 14.2.1 Multiple Myeloma - Market Size
    - 14.2.1.1 Market Size (2018-2023)
    - 14.2.1.2 Market Forecast (?2024-2034?)
  - 14.2.2 Multiple Myeloma - Market Size by Therapies



- 14.2.2.1 Market Size by Therapies (2018-2023)
- 14.2.2.2 Market Forecast by Therapies (?2024-2034?)
- 14.3 Market Scenario - United States
  - 14.3.1 Multiple Myeloma - Market Size
    - 14.3.1.1 Market Size (2018-2023)
    - 14.3.1.2 Market Forecast (?2024-2034?)
  - 14.3.2 Multiple Myeloma - Market Size by Therapies
    - 14.3.2.1 Market Size by Therapies (2018-2023)
    - 14.3.2.2 Market Forecast by Therapies (?2024-2034?)
  - 14.3.3 Multiple Myeloma - Access and Reimbursement Overview
- 14.4 Market Scenario - Germany
  - 14.4.1 Multiple Myeloma - Market Size
    - 14.4.1.1 Market Size (2018-2023)
    - 14.4.1.2 Market Forecast (?2024-2034?)
  - 14.4.2 Multiple Myeloma - Market Size by Therapies
    - 14.4.2.1 Market Size by Therapies (2018-2023)
    - 14.4.2.2 Market Forecast by Therapies (?2024-2034?)
  - 14.4.3 Multiple Myeloma - Access and Reimbursement Overview
- 14.5 Market Scenario - France
  - 14.5.1 Multiple Myeloma - Market Size
    - 14.5.1.1 Market Size (2018-2023)
    - 14.5.1.2 Market Forecast (?2024-2034?)
  - 14.5.2 Multiple Myeloma - Market Size by Therapies
    - 14.5.2.1 Market Size by Therapies (2018-2023)
    - 14.5.2.2 Market Forecast by Therapies (?2024-2034?)
  - 14.5.3 Multiple Myeloma - Access and Reimbursement Overview
- 14.6 Market Scenario - United Kingdom
  - 14.6.1 Multiple Myeloma - Market Size
    - 14.6.1.1 Market Size (2018-2023)
    - 14.6.1.2 Market Forecast (?2024-2034?)
  - 14.6.2 Multiple Myeloma - Market Size by Therapies
    - 14.6.2.1 Market Size by Therapies (2018-2023)
    - 14.6.2.2 Market Forecast by Therapies (?2024-2034?)
  - 14.6.3 Multiple Myeloma - Access and Reimbursement Overview
- 14.7 Market Scenario - Italy
  - 14.7.1 Multiple Myeloma - Market Size
    - 14.7.1.1 Market Size (2018-2023)
    - 14.7.1.2 Market Forecast (?2024-2034?)
  - 14.7.2 Multiple Myeloma - Market Size by Therapies

- 14.7.2.1 Market Size by Therapies (2018-2023)
- 14.7.2.2 Market Forecast by Therapies (?2024-2034?)
- 14.7.3 Multiple Myeloma - Access and Reimbursement Overview
- 14.8 Market Scenario - Spain
  - 14.8.1 Multiple Myeloma - Market Size
    - 14.8.1.1 Market Size (2018-2023)
    - 14.8.1.2 Market Forecast (?2024-2034?)
  - 14.8.2 Multiple Myeloma - Market Size by Therapies
    - 14.8.2.1 Market Size by Therapies (2018-2023)
    - 14.8.2.2 Market Forecast by Therapies (?2024-2034?)
  - 14.8.3 Multiple Myeloma - Access and Reimbursement Overview
- 14.9 Market Scenario - Japan
  - 14.9.1 Multiple Myeloma - Market Size
    - 14.9.1.1 Market Size (2018-2023)
    - 14.9.1.2 Market Forecast (?2024-2034?)
  - 14.9.2 Multiple Myeloma - Market Size by Therapies
    - 14.9.2.1 Market Size by Therapies (2018-2023)
    - 14.9.2.2 Market Forecast by Therapies (?2024-2034?)
  - 14.9.3 Multiple Myeloma - Access and Reimbursement Overview

## **15 MULTIPLE MYELOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **16 MULTIPLE MYELOMA MARKET - SWOT ANALYSIS**

- 16.1 Strengths
- 16.2 Weaknesses
- 16.3 Opportunities
- 16.4 Threats

## **17 APPENDIX**

## I would like to order

Product name: Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/M096770AFB17EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M096770AFB17EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

